title: Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.
abstract: The effect of solid-phase anti-CD3 antibody activation and cryopreservation was evaluated on thirteen samples of tumor-infiltrating lymphocytes (TILs) derived from epithelial ovarian cancer. Seven preparations of TILs were cultured with or without solid-phase anti-CD3 antibody in addition to 100 units/ml of recombinant interleukin-2 (rIL-2). The proliferation rate of all of the seven TIL preparations stimulated by anti-CD3 antibody on the fourth or fifth day of culture was 3.4 to 9.8 times greater than that of lymphocytes cultured with rIL-2 alone. Furthermore, in an experiment with five TIL samples activated with anti-CD3 antibody, three of them showed augmented cytotoxic activity against autologous fresh tumor cells. The population of CD3+/CD8+ TILs was increased after 4-5 weeks of cultivation and CD8+ lymphocytes amounted to over 70% in all of seven preparations tested, whereas two of seven preparations not activated by anti-CD3 antibody were CD3+/CD4(+)-dominant. In addition, nine preparations of TILs cultured with rIL-2 were cryopreserved for several weeks; after recovery from cryopreservation, no major change was observed in cell surface markers, in growth rate or in cytotoxic activity. These results suggest that cryopreserved and/or anti-CD3 antibody-activated lymphocytes could conveniently be employed in a clinical trial of adoptive immunotherapy employing TIL.
authors: Department of Obstetrics and Gynecology, Niigata University School of Medicine.
authors: H
authors: H
authors: Ikarashi
authors: Y
authors: Y
authors: Aoki
authors: K
authors: K
authors: Fujita
authors: S
authors: S
authors: Kodama
authors: K
authors: K
authors: Tanaka
mesh_terms: D000906:Antibodies / Q000494:pharmacology*; D017252:CD3 Complex / Q000276:immunology*; D015925:Cryopreservation; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D016246:Lymphocytes, Tumor-Infiltrating / Q000166:cytology / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D000906:Antibodies; D017252:CD3 Complex; D007376:Interleukin-2; D011994:Recombinant Proteins